159 related articles for article (PubMed ID: 22649315)
1. Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension.
Karasu-Minareci E; Ozbudak IH; Ozbilim G; Sadan G
ScientificWorldJournal; 2012; 2012():718279. PubMed ID: 22649315
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta.
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2006 Feb; 316(2):654-61. PubMed ID: 16204472
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of vardenafil as a calcium channel blocker in pulmonary artery in rats.
Minareci E; Sadan G
Indian J Pharmacol; 2014; 46(2):185-90. PubMed ID: 24741191
[TBL] [Abstract][Full Text] [Related]
5. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets.
Toque HA; Teixeira CE; Priviero FB; Morganti RP; Antunes E; De Nucci G
Br J Pharmacol; 2008 Jun; 154(4):787-96. PubMed ID: 18536732
[TBL] [Abstract][Full Text] [Related]
6. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
[TBL] [Abstract][Full Text] [Related]
7. The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension.
Fan YF; Zhang R; Jiang X; Wen L; Wu DC; Liu D; Yuan P; Wang YL; Jing ZC
Cardiovasc Res; 2013 Aug; 99(3):395-403. PubMed ID: 23650288
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of the relaxant effect of vardenafil in rat penile arteries.
Sánchez A; Villalba N; Martínez AC; García-Sacristán A; Hernández M; Prieto D
Eur J Pharmacol; 2008 May; 586(1-3):283-7. PubMed ID: 18420189
[TBL] [Abstract][Full Text] [Related]
9. Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release.
Toque HA; Priviero FB; Teixeira CE; Claudino MA; Baracat JS; Fregonesi A; De Nucci G; Antunes E
Urology; 2009 Jul; 74(1):216-21. PubMed ID: 19371941
[TBL] [Abstract][Full Text] [Related]
10. Improvement of exercise capacity in monocrotaline-induced pulmonary hypertension by the phosphodiesterase-5 inhibitor Vardenafil.
Schroll S; Sebah D; Wagner M; Popara V; Pfeifer M; Blumberg F
Respir Physiol Neurobiol; 2013 Mar; 186(1):61-4. PubMed ID: 23246673
[TBL] [Abstract][Full Text] [Related]
11. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats.
Morelli A; Filippi S; Sandner P; Fibbi B; Chavalmane AK; Silvestrini E; Sarchielli E; Vignozzi L; Gacci M; Carini M; Vannelli GB; Maggi M
J Sex Med; 2009 Jun; 6(6):1594-1608. PubMed ID: 19473460
[TBL] [Abstract][Full Text] [Related]
12. Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure.
Oudot A; Behr-Roussel D; Poirier S; Sandner P; Bernabé J; Alexandre L; Giuliano F
Eur Urol; 2011 Nov; 60(5):1020-6. PubMed ID: 21839578
[TBL] [Abstract][Full Text] [Related]
13. Vascular dysfunction induced by hypochlorite is improved by the selective phosphodiesterase-5-inhibitor vardenafil.
Radovits T; Arif R; Bömicke T; Korkmaz S; Barnucz E; Karck M; Merkely B; Szabó G
Eur J Pharmacol; 2013 Jun; 710(1-3):110-9. PubMed ID: 23623933
[TBL] [Abstract][Full Text] [Related]
14. The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus.
Radovits T; Bömicke T; Kökény G; Arif R; Loganathan S; Kécsán K; Korkmaz S; Barnucz E; Sandner P; Karck M; Szabó G
Br J Pharmacol; 2009 Mar; 156(6):909-19. PubMed ID: 19298393
[TBL] [Abstract][Full Text] [Related]
15. Powerful relaxation of phosphodiesterase type 4 inhibitor rolipram in the pig and human bladder neck.
Ribeiro ASF; Fernandes VS; Martínez-Sáenz A; Martínez P; Barahona MV; Orensanz LM; Blaha I; Serrano-Margüello D; Bustamante S; Carballido J; García-Sacristán A; Prieto D; Hernández M
J Sex Med; 2014 Apr; 11(4):930-941. PubMed ID: 24754330
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
17. Vardenafil ameliorates calcium mobilization in pulmonary artery smooth muscle cells from hypoxic pulmonary hypertensive mice.
Chen WS; Li XQ; Cao W; Xiao X; Dong L; Zhang JZ
Arch Med Res; 2012 May; 43(4):265-73. PubMed ID: 22704850
[TBL] [Abstract][Full Text] [Related]
18. Vardenafil and resveratrol synergistically enhance the nitric oxide/cyclic guanosine monophosphate pathway in corpus cavernosal smooth muscle cells and its therapeutic potential for erectile dysfunction in the streptozotocin-induced diabetic rat: preliminary findings.
Fukuhara S; Tsujimura A; Okuda H; Yamamoto K; Takao T; Miyagawa Y; Nonomura N; Okuyama A
J Sex Med; 2011 Apr; 8(4):1061-71. PubMed ID: 21269399
[TBL] [Abstract][Full Text] [Related]
19. Effects of atorvastatin and L-arginine treatments on electrical field stimulation-mediated relaxations in pulmonary arterial rings of monocrotaline-induced pulmonary hypertensive rats.
Ozturk EI; Uma S
J Cardiovasc Pharmacol; 2010 Nov; 56(5):498-505. PubMed ID: 20729759
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M
Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
